Announced
Completed
Financials
Tags
Biotechnology
Majority
Private Equity
Friendly
nucleic acids
biotechnology
France
biotech
Acquisition
Private
Single Bidder
Cross Border
Completed
Synopsis
A Warburg Pincus-led consortium completed the $597m in Polyplus, a developer of biotechnology used in gene and cell therapy. The investment is alongside existing majority shareholder, ArchiMed, a European private equity healthcare specialist. “The investment will enable us to further expand production capacity, fuel continued innovation in products, and support key growth initiatives. We’ll also focus on international expansion and increased hiring across technical, regulatory and commercial support functions,” Karsten Wilking, Polyplus CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.